Found: 195
Select item for more details and to access through your institution.
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1550, doi. 10.1002/ajh.27400
- By:
- Publication type:
- Article
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01052-4
- By:
- Publication type:
- Article
Risk models in myelofibrosis—the past, present, and future.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 519, doi. 10.1002/ajh.27270
- By:
- Publication type:
- Article
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 697, doi. 10.1002/ajh.27216
- By:
- Publication type:
- Article
Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 2, p. 1, doi. 10.1002/hon.3261
- By:
- Publication type:
- Article
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00968-7
- By:
- Publication type:
- Article
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. 68, doi. 10.1002/ajh.27136
- By:
- Publication type:
- Article
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00960-1
- By:
- Publication type:
- Article
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 12, p. 1829, doi. 10.1002/ajh.27079
- By:
- Publication type:
- Article
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 12, p. 1959, doi. 10.1002/ajh.27026
- By:
- Publication type:
- Article
Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. 1520, doi. 10.1002/ajh.27013
- By:
- Publication type:
- Article
Testing for rare types of Hereditary Hemochromatosis. A genetic study of two Italian families affected by early onset iron overload.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Resolving complex structural variants via nanopore sequencing.
- Published in:
- Frontiers in Genetics, 2023, p. 01, doi. 10.3389/fgene.2023.1213917
- By:
- Publication type:
- Article
Myeloid sarcoma: more and less than a distinct entity.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 8, p. 1973, doi. 10.1007/s00277-023-05288-1
- By:
- Publication type:
- Article
ABO blood group type and risk of venous thrombosis in essential thrombocythemia.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 3, p. 699, doi. 10.1111/bjh.18906
- By:
- Publication type:
- Article
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00887-7
- By:
- Publication type:
- Article
JAK2 inhibitor treatment of anemia in myelofibrosis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 7, p. 995, doi. 10.1002/ajh.26934
- By:
- Publication type:
- Article
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 11, p. 1681, doi. 10.1002/cncr.34707
- By:
- Publication type:
- Article
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1162990
- By:
- Publication type:
- Article
Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 1931, doi. 10.3390/cancers15071931
- By:
- Publication type:
- Article
Diagnostic and therapeutic challenges in mast cell sarcoma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 529, doi. 10.1002/ajh.26804
- By:
- Publication type:
- Article
Th e CXCR1/CXCR2 Inhibitor, Reparixin Reduces the Emperipolesis Between Neutrophils and Megakaryocytes in the Gata1<sup>low</sup> mice.
- Published in:
- Italian Journal of Anatomy & Embryology / Archivio Italiano di Anatomia Ed Embriologia, 2023, p. 160
- By:
- Publication type:
- Article
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 166, doi. 10.1002/ajh.26751
- By:
- Publication type:
- Article
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00786-x
- By:
- Publication type:
- Article
Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2023, v. 15, n. 1, p. 1, doi. 10.4084/MJHID.2023.028
- By:
- Publication type:
- Article
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis.
- Published in:
- Therapeutic Advances in Hematology, 2023, v. 14, p. 1, doi. 10.1177/20406207231205643
- By:
- Publication type:
- Article
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2023, v. 482, n. 1, p. 53, doi. 10.1007/s00428-022-03480-8
- By:
- Publication type:
- Article
Perioperative management of myeloproliferative neoplasms: A pan‐Canadian physician survey and international expert opinion.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. E466, doi. 10.1002/ajh.26739
- By:
- Publication type:
- Article
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1346, doi. 10.1002/jha2.591
- By:
- Publication type:
- Article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. E347, doi. 10.1002/ajh.26648
- By:
- Publication type:
- Article
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00713-6
- By:
- Publication type:
- Article
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 317, doi. 10.1111/bjh.18207
- By:
- Publication type:
- Article
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 846, doi. 10.1002/ajh.26548
- By:
- Publication type:
- Article
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 5, p. 626, doi. 10.1007/s12185-022-03335-7
- By:
- Publication type:
- Article
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 2, p. E35, doi. 10.1002/ajh.26423
- By:
- Publication type:
- Article
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00625-5
- By:
- Publication type:
- Article
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status.
- Published in:
- Liver International, 2022, v. 42, n. 2, p. 419, doi. 10.1111/liv.15148
- By:
- Publication type:
- Article
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 1, p. 139, doi. 10.1007/s00277-021-04683-w
- By:
- Publication type:
- Article
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221118429
- By:
- Publication type:
- Article
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 12, p. 1580, doi. 10.1002/ajh.26336
- By:
- Publication type:
- Article
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 12, p. 1, doi. 10.1038/s41408-021-00581-6
- By:
- Publication type:
- Article
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. 1472, doi. 10.1002/ajh.26332
- By:
- Publication type:
- Article
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. E408, doi. 10.1002/ajh.26305
- By:
- Publication type:
- Article
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. e850, doi. 10.1016/j.clml.2021.06.018
- By:
- Publication type:
- Article
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 244, doi. 10.1111/bjh.17727
- By:
- Publication type:
- Article
hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1 <sup> low </sup> Mutation in Mice.
- Published in:
- Frontiers in Genetics, 2021, v. 12, p. 1, doi. 10.3389/fgene.2021.720552
- By:
- Publication type:
- Article